Daniel Vitt - 16 Jul 2025 Form 4 Insider Report for IMMUNIC, INC. (IMUX)

Reporting relationship: CEO and Director, Director
Issuer ticker: IMUX
Reported as of: 16 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2025, 16:05:56 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 29 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Vitt

Key filing fact

Daniel Vitt filed Form 4 for IMMUNIC, INC. (IMUX) on 18 Jul 2025.

Key facts

This page summarizes Daniel Vitt's Form 4 filing for IMMUNIC, INC. (IMUX).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 18 Jul 2025, 16:05.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001773673 Primary reporting owner

Vitt Daniel

Relationship: CEO and Director, Director
Address: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK
Signature: /s/ Daniel Vitt
Signature date: 18 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMUX transaction Derivative

Stock Appreciation Right

Award

Transaction value: $0
Shares: +860,000
Change %
Price: $0.000000
Shares after: 860,000
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 860,000
Exercise price: $0.7700
Footnotes: F1

IMUX transaction Derivative

Stock Appreciation Right

Award

Transaction value: $0
Shares: +1,720,000
Change %
Price: $0.000000
Shares after: 1,720,000
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,720,000
Exercise price: $0.7700
Footnotes: F1, F2

IMUX transaction Derivative

Stock Appreciation Right

Award

Transaction value: $0
Shares: +1,720,000
Change %
Price: $0.000000
Shares after: 1,720,000
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,720,000
Exercise price: $0.7700
Footnotes: F1, F3

IMUX transaction Derivative

Stock Appreciation Right

Award

Transaction value: $0
Shares: +860,000
Change %
Price: $0.000000
Shares after: 860,000
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 860,000
Exercise price: $0.7700
Footnotes: F1, F4

IMUX transaction Derivative

Stock Appreciation Right

Award

Transaction value: $0
Shares: +860,000
Change %
Price: $0.000000
Shares after: 860,000
Date: 16 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 860,000
Exercise price: $0.7700
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.

Footnote F2

Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof.

Footnote F3

Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof.

Footnote F4

Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering").

Footnote F5

Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.